T1	p 326 346	distress , cigarette
T2	p 401 418	cigarettes smoked
T3	p 647 665	Center for Tobacco
T4	p 709 714	USA .
T5	p 728 793	A total of 403 adult , daily smokers without contraindications to
T6	i 33 70	bupropion sustained-release treatment
T7	i 174 218	bupropion sustained-release ( SR ) treatment
T8	i 292 302	abstinence
T9	i 465 467	SR
T10	i 550 568	placebo-controlled
T11	i 587 604	bupropion SR were
T12	i 694 701	Madison
T13	i 704 706	WI
T14	i 709 712	USA
T15	i 794 812	bupropion SR use .
T16	i 875 881	9-week
T17	i 892 924	bupropion SR or placebo pill and
T18	i 942 997	brief individual counseling sessions or no counseling .
T19	i 1128 1129	.
T20	i 1161 1173	equation and
T21	i 1237 1259	bupropion SR treatment
T22	i 1395 1402	partial
T23	i 1487 1499	Bupropion SR
T24	i 1674 1681	support
T25	i 1696 1718	bupropion SR treatment
T26	i 1809 1811	SR
T27	o 282 354	post-quit abstinence , including withdrawal distress , cigarette craving
T28	o 357 400	positive affect and subjective reactions to
T29	o 440 451	specificity
T30	o 455 475	bupropion SR effects
T31	o 702 703	,
T32	o 1043 1093	ratings of smoking behavior and putative mediators
T33	o 1161 1169	equation
T34	o 1269 1290	short-term abstinence
T35	o 1303 1322	withdrawal distress
T36	o 1340 1358	subjective effects
T37	o 1428 1455	cigarette craving reduction
T38	o 1487 1496	Bupropion
T39	o 1511 1538	point-prevalence abstinence
T40	o 1550 1559	post-quit
T41	o 1601 1639	motivation to quit and self-efficacy .
T42	o 1723 1730	relapse